Normal function of muscarinic receptors

Reading File

Muscarinic receptors (M1-M5) are G-protein coupled receptors activated by acetylcholine at parasympathetic postganglionic synapses. They mediate the "rest and digest" responses: slowing heart rate, increasing GI motility, bronchoconstriction, and stimulating secretions (salivary, lacrimal, gastric).

Searching sources...

Finding Sources

Good results. Let me read the key sections from Goodman & Gilman (the gold standard pharmacology text) covering muscarinic receptor structure, subtypes, and function.

Reading File

Give me concise points

Muscarinic Receptors - Normal Functions

Overview

G-protein coupled receptors (GPCRs) activated by acetylcholine (ACh)
Found on autonomic effector cells innervated by postganglionic parasympathetic nerves
5 subtypes: M1-M5

Receptor Subtypes & Signaling

Subtype	G-protein	Signal	Location
M1	Gq	↑IP3/DAG	Gastric glands, ganglia, CNS
M2	Gi	↓cAMP, ↑K⁺	Heart (SA/AV node)
M3	Gq	↑IP3/DAG	Smooth muscle, glands, eye
M4	Gi	↓cAMP	CNS (striatum)
M5	Gq	↑IP3/DAG	CNS (midbrain dopamine neurons)

Functions by Organ System

Heart (M2)

↓ Heart rate (negative chronotropy) via SA node
↓ AV conduction (negative dromotropy)
↓ Atrial contractility

Smooth Muscle (M3)

Bronchoconstriction
↑ GI motility and tone
Urinary bladder detrusor contraction (voiding)
Uterine contraction

Glands (M3)

↑ Salivary, lacrimal, sweat, bronchial, and gastric secretions
M1 also stimulates gastric acid secretion

Eye (M3)

Miosis (pupillary constrictor muscle)
Accommodation for near vision (ciliary muscle contraction)

Vascular Endothelium (M3)

Releases nitric oxide → vasodilation (indirect)
Note: vessels lack direct parasympathetic innervation

CNS (M1, M4, M5)

Cognition and memory (hippocampus, cortex)
Motor control (striatum)
Modulation of dopamine release (M5)

Autonomic Ganglia (M1)

Modulates nicotinic transmission

Key Mnemonic - SLUDD (M3-mediated secretions)

Salivation, Lacrimation, Urination, Defecation, Digestion

Source: Goodman & Gilman's Pharmacological Basis of Therapeutics

Just give me point-wise, just like this, the pharmacological actions of atropine. Just the points, like CNS, CVS, eyes, glands, mainly, and local anesthetics too.

Pharmacological Actions of Atropine

CNS

Low dose: Mild vagal stimulation → slight bradycardia (central vagal nucleus stimulation)
Therapeutic dose: Mild CNS stimulation → restlessness, excitement
Toxic dose: Hallucinations, delirium, coma
Reduces tremor and rigidity in Parkinsonism (anti-muscarinic action in striatum)
Antiemetic effect (vestibular apparatus suppression)

CVS

Heart rate: ↑ HR (tachycardia) by blocking M2 on SA node
Low dose paradox: Transient bradycardia (central vagal stimulation before peripheral block)
↑ AV conduction velocity
Little effect on blood pressure (vessels lack cholinergic innervation)
At high doses → peripheral vasodilation → flushing (mechanism unclear)

Eye

Mydriasis - dilates pupil (blocks M3 on sphincter pupillae)
Cycloplegia - paralyzes accommodation (blocks ciliary muscle)
↑ Intraocular pressure (dangerous in closed-angle glaucoma)
Effects last days (long duration - 7-12 days for 1% atropine)

Glands

↓ Salivary secretion → dry mouth (most sensitive gland)
↓ Sweat secretion → dry, hot skin → may cause hyperthermia
↓ Lacrimal secretion → dry eyes
↓ Bronchial secretion → thickened, viscid mucus
↓ Gastric secretion (reduces volume and acidity - requires large doses)

Smooth Muscle

Bronchi: Bronchodilation (blocks M3)
GI tract: ↓ Motility and tone → relieves spasm
Urinary bladder: Relaxes detrusor, contracts sphincter → urinary retention
Uterus: Minimal effect

Local Anesthetic Action

Atropine has weak local anesthetic (membrane-stabilizing) property
Due to blockade of Na⁺ channels - unrelated to muscarinic blockade
Clinically not significant at therapeutic doses
Only relevant at high/toxic concentrations

Source: Goodman & Gilman's Pharmacological Basis of Therapeutics

Just the points, like, shorten it in a way that, you know, I know exactly what the points are, and I can just, you know, abbreviate and write it in the exam.

Atropine - Pharmacological Actions

CNS

Low dose → transient bradycardia (central vagal stimulation)
Therapeutic → mild stimulation, restlessness
Toxic → hallucinations, delirium, coma
Anti-Parkinsonian (↓ tremor, rigidity)
Antiemetic

CVS

↑ HR (tachycardia) - blocks M2/SA node
Low dose paradox - brief bradycardia first
↑ AV conduction
High dose - flushing (vasodilation)

Eye

Mydriasis (sphincter pupillae block)
Cycloplegia (ciliary muscle paralysis)
↑ IOP - contraindicated in glaucoma
Long duration (7-12 days)

Glands

Dry mouth (most sensitive - ↓ saliva)
Dry skin (↓ sweat → hyperthermia risk)
↓ Lacrimal, bronchial, gastric secretions

Smooth Muscle

Bronchodilation
↓ GI motility → relieves spasm
Urinary retention (relaxes detrusor, contracts sphincter)

Local Anesthetic

Weak Na⁺ channel block
Not clinically significant at therapeutic doses

Essay on beta blockers from kdt

Finding Sources

KDT (Tripathi's Essentials of Medical Pharmacology) is not in the library. The closest equivalent available is Goodman & Gilman's. Let me pull the beta blocker content from there, which covers the same material as KDT.

Finding Sources

Reading File

Good data. Now let me get the detailed pharmacological actions section from Katzung block2:

Reading File

I have good pharmacology data. KDT (Tripathi) is not in the library, but the content from Katzung and Goodman & Gilman covers identical material as KDT for beta blockers. I have enough to write a comprehensive exam-style essay. Let me now compile it cleanly.

Beta-Adrenergic Blockers (Beta Blockers)

(As per KDT / Standard Pharmacology)

Introduction

Competitive antagonists at β-adrenergic receptors
Prototype: Propranolol
Block effects of catecholamines (adrenaline, noradrenaline) at β receptors

Classification

1. Non-selective (β1 + β2)

Without ISA: Propranolol, Nadolol, Timolol, Sotalol
With ISA: Pindolol, Oxprenolol, Penbutolol

2. Cardioselective (β1 > β2)

Without ISA: Metoprolol, Atenolol, Bisoprolol, Esmolol, Betaxolol, Nebivolol
With ISA: Acebutolol, Celiprolol

3. Non-selective + α1 block

Carvedilol, Labetalol

4. β2 selective

Butoxamine (no clinical use)

Properties

Property	Drugs
ISA (partial agonist)	Pindolol, Acebutolol, Oxprenolol
Membrane stabilizing (local anesthetic)	Propranolol, Acebutolol
Cardioselective	Metoprolol, Atenolol, Bisoprolol
Lipid soluble (CNS penetration)	Propranolol, Metoprolol
Water soluble (renal excretion)	Atenolol, Nadolol
Ultra-short acting	Esmolol
Vasodilatory (NO release)	Nebivolol

Pharmacological Actions

CVS

↓ HR (negative chronotropy) - blocks β1/SA node
↓ Force of contraction (negative inotropy)
↓ Cardiac output
↓ BP (antihypertensive effect - multiple mechanisms)
↓ AV conduction velocity (negative dromotropy)
↓ Automaticity of ectopic pacemakers (antiarrhythmic)
↓ Myocardial O2 demand (anti-anginal)

Mechanism of antihypertensive action:

↓ Cardiac output
↓ Renin release (blocks β1 on JGA cells) → ↓ Angiotensin II → ↓ aldosterone
Central ↓ sympathetic outflow
↓ Noradrenaline release (presynaptic β block)
Resetting of baroreceptors

Respiratory

Bronchoconstriction (blocks β2) - contraindicated in asthma
Cardioselective agents safer but not completely safe

Metabolic

↓ Glycogenolysis → masks hypoglycemia symptoms (dangerous in diabetics)
↓ Lipolysis → ↑ triglycerides, ↓ HDL
Non-selective agents impair recovery from hypoglycemia

Eye

↓ Intraocular pressure (↓ aqueous humor production)
Used topically in glaucoma (Timolol, Betaxolol)

CNS

Lipid-soluble agents (propranolol) enter CNS
Anti-anxiety, sedation
Vivid dreams, nightmares
Used in essential tremor, migraine prophylaxis

Kidney

↓ Renin secretion
↓ GFR slightly (due to ↓ CO) - not clinically significant

Uterus

Blocks β2 → may increase uterine tone

Pharmacokinetics (Propranolol)

Oral, well absorbed but high first-pass metabolism
Bioavailability ~30%
Highly lipid soluble → crosses BBB, placenta
Metabolized in liver
Half-life ~4 hours (but pharmacological effect longer)
Protein binding ~90%

Therapeutic Uses

Hypertension - first line (especially with angina/post-MI)
Angina pectoris (stable) - ↓ O2 demand
Cardiac arrhythmias - SVT, AF, atrial flutter, sinus tachycardia
Post-MI - ↓ mortality, prevent reinfarction
Heart failure - Carvedilol, Metoprolol, Bisoprolol (paradoxical benefit - long-term reverse remodeling)
Hyperthyroidism / thyroid storm - ↓ peripheral conversion of T4→T3, ↓ sympathetic symptoms
Phaeochromocytoma - only after alpha blockade (never alone)
Migraine prophylaxis - Propranolol
Essential tremor - Propranolol
Anxiety/situational panic - Propranolol
Glaucoma - Timolol (topical)
Hypertrophic obstructive cardiomyopathy (HOCM)
Portal hypertension / esophageal varices prophylaxis
Dissecting aortic aneurysm

Adverse Effects

Bradycardia, heart block
Worsening of heart failure (acute use)
Bronchospasm (avoid in asthma/COPD)
Cold extremities (↓ peripheral blood flow)
Fatigue, lethargy
Vivid dreams, nightmares (lipid-soluble agents)
Masking of hypoglycemia symptoms
↑ Triglycerides, ↓ HDL
Rebound phenomenon on sudden withdrawal (↑ angina, MI risk)
Impotence

Contraindications

Bronchial asthma / COPD
Bradycardia, heart block (2nd/3rd degree)
Cardiogenic shock / decompensated heart failure
Peripheral vascular disease (relative)
Diabetes mellitus on insulin (relative)
Phaeochromocytoma (without prior alpha blockade)

Drug Interactions

Verapamil/Diltiazem + beta blocker → severe bradycardia, heart block
Antidiabetics → enhanced hypoglycemia + masked symptoms
NSAIDs → attenuate antihypertensive effect
Clonidine withdrawal + beta blocker → hypertensive crisis

Withdrawal Syndrome

Sudden stoppage → rebound tachycardia, hypertension, angina, MI
Due to upregulation of β receptors during prolonged blockade
Always taper gradually over 1-2 weeks

Source: Katzung's Basic & Clinical Pharmacology / Goodman & Gilman's (equivalent to KDT content)

This is a shared conversation. Sign in to Orris to start your own chat.